relatlimab   Click here for help

GtoPdb Ligand ID: 9536

Synonyms: BMS-986016 | BMS986016 | ONO-4482 | Opdualag® (nivolumab + relatlimab-rmbw) | relatlimab-rmbw
Approved drug Immunopharmacology Ligand
relatlimab is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Relatlimab (BMS-986016) is an anti-LAG3 monoclonal antibody that was developed for utility in cancer immunotherapy.
References
1. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI et al.. (2004)
Role of LAG-3 in regulatory T cells.
Immunity, 21 (4): 503-13. [PMID:15485628]
2. Lonberg N, Srinivasan M. (2014)
Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof.
Patent number: WO2014008218. Assignee: Bristol-Myers Squibb Company. Priority date: 02/07/2012. Publication date: 09/01/2014.
3. Nguyen LT, Ohashi PS. (2015)
Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Nat Rev Immunol, 15 (1): 45-56. [PMID:25534622]
4.  Fully human monoclonal antibody specific for lymphocyte activation gene 3 and nivolumab.
Accessed on 21/09/2017. Modified on 21/09/2017. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=595017